Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17925137 | 1.00 | MAPK14 (0.39) | MAPK14ALDH1A1NPSR1CA2HPGD | |
| SCHEMBL849700 | 0.86 | CA2 (0.43) | MAPK14ALDH1A1NPSR1CA2TSHR | |
| SCHEMBL849701 | 0.86 | CA2 (0.43) | MAPK14ALDH1A1NPSR1CA2TSHR | |
| SCHEMBL13064749 | 0.85 | MAPK14 (0.44) | MAPK14ALDH1A1NPSR1HPGDTSHR | |
| SCHEMBL10291491 | 0.81 | ALDH1A1 (0.38) | MAPK14ALDH1A1NPSR1CA2HPGD | |
| SCHEMBL16013097 | 0.78 | MAPK14 (0.40) | MAPK14ALDH1A1NPSR1CA2HPGD | |
| SCHEMBL7964858 | 0.78 | ADRA1B (0.49) | MAPK14ADRA1AADRA1BHTR1AADRA1D | |
| SCHEMBL16013174 | 0.77 | MAPK14 (0.38) | MAPK14ALDH1A1NPSR1CA2ADRA1A | |
| SCHEMBL5766219 | 0.77 | MAPK14 (0.43) | MAPK14ALDH1A1NPSR1CA2KDM4E | |
| SCHEMBL2215555 | 0.77 | MAPK14 (0.43) | MAPK14ALDH1A1NPSR1CA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055288-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3055288-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| US-9932311-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932311-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932311-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-04-03 | — | — | US | disclosed |
| EP-3055288-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160207887-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-07-21 | — | — | US | disclosed |
| US-20160207887-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-07-21 | — | — | US | disclosed |
| US-20160207887-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-07-21 | — | — | US | disclosed |
| WO-2015051725-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015051725-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207887-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR55 | MAPK14 1857/4885ALDH1A1 3088/4885NPSR1 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.